UNFUCG
DashboardSearchChatBookmarksNotificationsActivityPremiumProfile
?
Home
Search
Chat
Saved
Profile
Episode
The Drugs Dr Brad Takes for a Longer, Healthier Life
~24 min
Episode Brief·YouTube

The Drugs Dr Brad Takes for a Longer, Healthier Life

Brad Stanfield
Watch on YouTube Add to chat My bookmarks← All sources

TL;DR

The four things you'd lose by not watching

4 items

TL;DR

The four things you'd lose by not watching

4 items
1

Dr. Brad Stanfield, a 33-year-old GP with a healthy lifestyle and a family history of hypertension, discovered his home blood pressure was consistently 140–150 mmHg despite a reassuring 120 mmHg clinic reading under an anxiolytic.

2

He lowered his blood pressure to 120 mmHg using candesartan 16 mg (an ARB) and empagliflozin 12.5 mg (an SGLT2 inhibitor), an unconventional antihypertensive for non-diabetics that required a kidney specialist’s sign-off and cut 25 mg tablets in half to save money.

3

Empagliflozin raised his LDL cholesterol, so he added ezetimibe to rosuvastatin 5 mg, slashing LDL from 1.9 mmol/L (73 mg/dL) to 0.9 mmol/L (35 mg/dL), far below his personal target of <1.4 mmol/L (<54 mg/dL) based on the PESA study.

4

To reduce the risk of statin-induced diabetes while keeping LDL low, he swapped rosuvastatin for pravastatin 20 mg taken at night, exploiting its short half-life and lower diabetes risk, demonstrating a personalized pharmacologic optimization on top of an excellent diet and exercise.

What's new

Personal practice updates, fresh positions, predictions

2 items

False reassurance from in-clinic blood pressure readings

Start of transcript

Dr. Stanfield’s clinic blood pressures—140 mmHg during medical school and 120 mmHg under the relaxant adazzylam—gave a false sense of security. Only after buying a home monitor did he find his true BP was 140–150 mmHg, hidden by a drug-induced low reading and outdated teaching.

Why this matters: Even a doctor fell for misleading measurements and now warns that single clinic readings can mask dangerous familial hypertension, especially in young, fit people.

Background

In 2011, 140 mmHg was considered acceptable, but now BP targets are <120 mmHg. His relaxant-altered measurement mimicked normalcy, leading him to believe his family history hadn’t caught up with him.

Dr. Stanfield recounts how, as a second-year medical student in 2011, his classmates measured his BP at 140, which at the time was thought to be okay. Later, in 2013, a procedure under adazzylam (a benzodiazepine) gave a reading of 120 — a number that seemed to confirm all was well. He now realizes that the drug, like ‘a few pints of beer’, lowered his BP artifactually. Despite knowing his thin, fit family members still needed BP medications, he remained falsely reassured. When he finally followed his own advice and measured repeatedly at home, he was ‘horrified’ to see 140–150 mmHg, forcing him to confront his inherited hypertension and start drug therapy. This experience underscores the danger of relying on sporadic office readings and highlights the value of self-monitoring.

Personal experience

He himself admits he should have bought a home monitor years earlier and felt deep disappointment that he hadn’t practiced what he preaches. The revelation drove him to meticulously track and treat his BP.

I was horrified when I was measuring my blood pressure. So consistently, I was getting measurements at about 140 to 150.

Also said
“At that point I had some adazzylam on board which is a relaxant. Basically it’s like having a few pints of beer. So obviously my blood pressure was going to be quite low because I was lying down and I was all nicely relaxed because I had these other drugs on board.”— Explains why a sedated 120 mmHg reading fooled him into ignoring his true home numbers.
“I’m glad that I finally followed my own advice, but I should have done it a heck of a lot earlier.”— Candid self-criticism from a doctor who delayed acting on his own guidance.

Setting LDL target <1.4 mmol/L (54 mg/dL) based on PESA study

Discussion of LDL lowering strategy

Using the PESA study finding that people with LDL 50–60 mg/dL developed no atherosclerotic plaque, Dr. Stanfield set a personal LDL target well below standard primary prevention goals, driving him to use combination lipid-lowering therapy.

Why this matters: Most guidelines accept LDL <100 mg/dL or <70 mg/dL for high risk. He applies a more aggressive imaging-based threshold to a metabolically healthy individual, justifying pharmacologic intensification.

Background

His baseline LDL was 1.9 mmol/L (73 mg/dL), considered ‘pretty good’. The PESA study in individuals with otherwise perfect metabolic health showed no plaque progression only when LDL was in the 50–60 mg/dL range.

Dr. Stanfield cites the PESA study, where participants had normal weight, blood pressure, and insulin sensitivity — the sole variable was LDL. Those with LDL around 50–60 mg/dL showed no plaque development. He decided to aim for that zone, not just ‘normal’. He initially used rosuvastatin 5 mg to reach 1.6 mmol/L, later added ezetimibe after empagliflozin nudged LDL up, dropping him to 0.9 mmol/L (35 mg/dL). With such low LDL, he could then de-escalate statin potency to reduce diabetes risk while staying under his PESA-inspired goal. This aggressive targeting is a personal choice, not a universal recommendation, but it showcases how emerging imaging data can influence individual prevention strategies.

Personal experience

He himself adopted this target and tracked it across multiple blood tests, using it to guide each medication change.

I use that as a justification for me personally to aim for lower LDL cholesterol levels.

Also said
“From the piece of study results… when the LDL cholesterol is around 50 to 60, there was no plaque development in blood vessels.”— The core evidence that shifted his personal LDL goal.

Recommendations

Products, supplements, and tools mentioned in the episode

3 items

At‑home blood pressure monitor

Tool

Dr. Stanfield strongly advises patients to monitor blood pressure at home. He personally bought one and discovered his true hypertensive numbers, which changed his entire health trajectory.

He highlights how a simple, widely available tool can unmask hypertension that clinic readings miss due to white‑coat effects or sedatives. He regrets not buying one earlier and now performs regular home checks.

vs alternatives

He contrasts home readings with clinic readings, showing that the former are far more reliable.

Personal experience

He used a home monitor to uncover his own BP of 140–150 mmHg, leading to pharmacologic intervention.

I need to buy an at home blood pressure monitor and actually see what my blood pressure is and make sure that it truly is at 120 and not at that 140 to 150 level.

Also said
“I was horrified when I was measuring my blood pressure. So consistently, I was getting measurements at about 140 to 150.”— Illustrates the dramatic difference home monitoring can reveal.
Find At‑home

Gardian (empagliflozin) 25 mg tablets, cut in half for 12.5 mg dosing

Product

Dr. Stanfield uses empagliflozin under the brand Gardian off‑label for hypertension, splitting the 25 mg tablet to approximate a 10–12.5 mg dose as part of his blood pressure regimen after specialist approval.

He chose Gardian (empagliflozin) because of its dual BP and metabolic benefits. Since the 25 mg tablet is more cost‑effective, he physically cuts it to achieve the desired 12.5 mg. He emphasizes that this is a prescription medication requiring specialist sign‑off for non‑standard use.

vs alternatives

He considered a calcium channel blocker as the traditional next‑line agent, but preferred empagliflozin for its additional longevity and metabolic data.

Personal experience

He personally takes this split tablet daily after his GP and kidney specialist approved the off‑label indication.

Here’s the medication that I’m on. So it’s called So the brand name is called Gardian. There you go. Uh impecc… I cut these medication these pills in half so that I’m getting 12 1/2 millig which is roughly the 10 millig dose that I want.

Find Gardian

Azetto (ezetimibe)

Product

Dr. Stanfield added Azetto (ezetimibe) to his rosuvastatin regimen to block gut cholesterol absorption, pushing his LDL from 1.5 mmol/L to 0.9 mmol/L.

Ezetimibe is a cholesterol absorption inhibitor that complements the statin’s effect on liver synthesis. He chose the brand Azetto and experienced a dramatic LDL drop, which later gave him flexibility to reduce statin intensity.

vs alternatives

Instead of increasing the statin dose, he added ezetimibe to achieve a greater LDL reduction with fewer side‑effect concerns.

Personal experience

He personally took Azetto alongside rosuvastatin and saw his LDL plunge to 0.9 mmol/L.

I wanted to add in a medication called Azetto. Where are we? There we go. Azetam. So, Azetami works by telling the gut to not absorb as much cholesterol.

Also said
“Together they work really well to lower the overall blood cholesterol levels.”— Summarizes the synergy between ezetimibe and the statin.
Find Azetto

Notable quotes

Lines worth pulling out — contrarian, specific, or perfectly phrased

1 item
I cut these medication these pills in half so that I’m getting 12 1/2 millig which is roughly the 10 millig dose that I want.
A practical, money‑saving hack for off‑label dosing that many listeners wouldn’t expect from a doctor’s own regimen.

Sign in to share feedback

Tell us if this brief hit the mark or missed it — feedback feeds back into the next iteration of the prompt.

Topics covered

home-blood-pressure-monitoringfamilial-hypertensionmisdiagnosis-of-hypertensioncandesartanangiotensin-receptor-blockerempagliflozinsglt2-inhibitorblood-pressure-target-120combination-low-dose-pharmacotherapyldl-cholesterol-targetpesa-studyrosuvastatinezetimibedual-cholesterol-loweringstatin-induced-diabetespravastatinnighttime-dosingcost-saving-tablet-splittingdoctor-as-patientlongevity-pharmacology
Free account

Make this library yours

Reading is free for everyone. A free account adds the personal layer: save protocols, follow experts, and see how the other experts weigh in on this same topic.

Create a free accountSign in

Where the experts disagree — weekly

One email a week: the sharpest new disagreements and protocols from the library. No spam, unsubscribe anytime.

Educational summary of the cited expert source — not medical advice. Open the source recording linked above and consult a qualified physician before acting on any protocol.